Roche and its Genentech unit plan to invest nearly $900 million in the next five years to expand global manufacturing. Roche will spend nearly $600 million to expand sites in Penzberg, German and Basel, Switzerland, while Genentech will invest more than $285 million to expand the Vacaville and Oceanside, CA sites. The investment will support increasing demand for licensed biologic medicines, such as RoActemra, Kadcyla and Perjeta, as well as provide a foundation for the delivery of 39 investiga...